| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate. [Wikipedia] |
| Indication |
For the treatment of moderate or severe hypercalcemia associated with malignancy |
| Pharmacology |
Pamidronate is in a class of drugs called bisphosphonates. Pamidronate reduces breakdown of the bones. Pamidronate is used in the treatment of Paget's disease of bone; to reduce high levels of calcium in the blood associated with malignancy (cancer); and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma. |
| Toxicity |
Side effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Pamidronate is not metabolized and is exclusively eliminated by renal excretion |
| Absorption |
Plasma concentration rises rapidly upon IV administration. |
| Half Life |
The mean ± SD elimination half-life is 28 ± 7 hours |
| Protein Binding |
Approximately 54% to human serum proteins. |
| Elimination |
Pamidronate is not metabolized and is exclusively eliminated by renal excretion. |
| Clearance |
* 107 +/- 50 mlL/min |
| References |
| • |
Zarychanski R, Elphee E, Walton P, Johnston J: Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006 Jan;81(1):73-5.
[Pubmed]
|
|
| External Links |
|